Shivaani Kummar, MD
Enriched profileDirector, OHSU Knight Cancer Institute; Margaret and Lester DeArmond University Chair of Molecular Oncology; Chief, Division of Hematology and Medical Oncology, OHSU School of Medicine · Oregon Health & Science University (OHSU)
Shivaani Kummar is Director, OHSU Knight Cancer Institute; Margaret and Lester DeArmond University Chair of Molecular Oncology; Chief, Division of Hematology and Medical Oncology, OHSU School of Medicine at Oregon Health & Science University (OHSU). OpenAlex indexes 649 publications with 15,335 citations (h-index 59); ClinicalTrials.gov lists 21 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 13 Oct 2026
Shivaani Kummar is Director, OHSU Knight Cancer Institute at Oregon Health & Science University (OHSU). The public record shows 649 publications with 15,335 citations (h-index 59), centered on Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, PARP inhibition in cancer therapy. It also documents an investigator role on 21 registered clinical trials, industry payments reported by 12 companies, 3 NIH-funded awards (2021–2026).
- Most recent indexed publication: 2026 · JCO precision oncology
- Top research focus: Lung Cancer Treatments and Mutations
- 21 registered trials on ClinicalTrials.gov
- Open Payments reporting from 12 companies
Generated from the cited public record · current as of 13 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 21 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 181.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Member
National Cancer Policy Forum (National Academies of Sciences, Engineering, and Medicine), contributes to identifying national high-priority policy issues in cancer research and care …
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ncbi.nlm.nih.gov ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 13 Oct 2026
Listed as an investigator on 21 registered studies on ClinicalTrials.gov. The most recent:
- Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
Sponsor: OHSU Knight Cancer Institute
- SW-682 in Advanced Solid Tumors
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry payments
Updated 13 Oct 2026
12 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim International GmbHProgram year20251 payment
- Daiichi Sankyo Inc.Program year20252 payments
- Bayer Healthcare Pharmaceuticals Inc.Program year20251 payment
NIH funding
Updated 13 Oct 2026
3 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:
- Experimental Therapeutics in Cancer Training Program
Oregon Health & Science University
FY2026$268,200T32CA285265
Congress activity
Updated 13 Oct 2026
155 congress contributions (2004–2025) across AACR, ASCO, ESMO per OpenAlex. The most recent:
- Abstract CT153: First in human phase 1 trial of the SRC family kinase inhibitor NXP900 in patients with advanced solid tumors
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 13 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors.
Clinical cancer research
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)Network
Updated 13 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 13 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/shivaani-kummar-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Shivaani-Kummar-38434138
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - LinkedIn
linkedin.com/in/shivaani-kummar-b51a161b9
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
news.ohsu.edu/2025/03/20/shivaani-kummar-appointed-interim-chief-executive-of-the-knight-cancer-institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.ohsu.edu ↗ - YouTube
onclive.com/view/kummar-on-the-investigation-of-rezatapopt-in-tp53-y220c-mutated-advanced-solid-tumors
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 13 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →shop.elsevier.com ↗
- Member
American Society of Clinical Oncology (ASCO)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗ - Member
American Association for Cancer Research (AACR)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
Awards & honors
honors on the public record- Fellow
American College of Physicians (FACP)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗ - Appointed Member
National Cancer Policy Forum, National Academies of Sciences, Engineering, and Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.ohsu.edu ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.ohsu.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.ohsu.edu ↗
- Co-Director
Center for Experimental Therapeutics, Knight Cancer Institute, OHSU
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohsu.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- Regular contributor/interviewee
OncLive (video interviews on early-phase trial data)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Jonathan Purnell, MD
Oregon Health & Science University (OHSU)
Charles Blanke, MD
Oregon Health & Science University (OHSU)
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center